Ritter Pharmaceuticals, Inc. (RTTR) Analysts See $-0.05 EPS

February 14, 2018 - By Lynda A. Deweese

 Ritter Pharmaceuticals, Inc. (RTTR) Analysts See $ 0.05 EPS

Analysts expect Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) to report $-0.05 EPS on February, 26.They anticipate $0.69 EPS change or 93.24 % from last quarter’s $-0.74 EPS. After having $-0.14 EPS previously, Ritter Pharmaceuticals, Inc.’s analysts see -64.29 % EPS growth. The stock increased 1.28% or $0.0038 during the last trading session, reaching $0.3018. About 199,997 shares traded. Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) has declined 56.21% since February 14, 2017 and is downtrending. It has underperformed by 72.91% the S&P500.

Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Ratings Coverage

Among 5 analysts covering Ritter Pharmaceuticals (NASDAQ:RTTR), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Ritter Pharmaceuticals had 9 analyst reports since December 2, 2015 according to SRatingsIntel. As per Thursday, April 14, the company rating was initiated by Maxim Group. The rating was maintained by Roth Capital on Monday, June 5 with “Buy”. The firm earned “Hold” rating on Friday, August 4 by Maxim Group. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 23. Rodman & Renshaw initiated the shares of RTTR in report on Wednesday, January 4 with “Buy” rating. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, October 25. As per Wednesday, December 2, the company rating was initiated by Chardan Capital Markets. The rating was maintained by Maxim Group with “Hold” on Wednesday, July 5.

Ritter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The company has market cap of $14.94 million. The Company’s lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. It currently has negative earnings. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine.

More notable recent Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) news were published by: Globenewswire.com which released: “Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on …” on November 29, 2017, also Globenewswire.com with their article: “Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and …” published on October 31, 2017, Valuewalk.com published: “MabVax Therapeutics Holdings, Inc. (MBVX) reports 4.99% activist investor …” on February 14, 2018. More interesting news about Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) were released by: Globenewswire.com and their article: “Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business …” published on November 02, 2017 as well as Globenewswire.com‘s news article titled: “Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical …” with publication date: January 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.